VGXI Inc, a Texas-based contract developer and manufacturer (CDMO) specialising in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines and RNA medicines, announced on Wednesday the appointment of Stephanie Burke as chief accounting officer (CAO).
Burke has more than a decade of accounting and leadership expertise. She has served in leadership roles managing both the VGXI Accounting/Finance and Materials teams.
Previously, Burke was financial controller at Manuli RYCO / Fliuconnecto and general manager of International Expo Service.
VGXI's CEO, Young Park, said: "Stephanie has been an invaluable member of the VGXI team since 2015. Her exceptional financial acumen coupled with her leadership skills make her the ideal candidate for the chief accounting officer position.
"This well-deserved promotion recognises the significant contributions Stephanie has made to VGXI during her tenure and she will undoubtedly play a critical role in shaping our financial strategies as we enter our next phase."
FDA extends Biohaven's PDUFA date for troriluzole NDA for spinocerebellar ataxia
AbbVie and ADARx Pharmaceuticals partner on next-generation siRNA therapies
Clarivate adds Pathway Maps to OFF-X, boosting drug safety intelligence
GSK to acquire efimosfermin in USD2bn deal to expand hepatology pipeline
Hemogenyx Pharmaceuticals expands HG-CT-1 trial to include paediatric AML patients
Cumberland Pharmaceuticals partners Qureight for idiopathic pulmonary fibrosis treatment research
Hoth Therapeutics reports positive HT-KIT preclinical results
Solve M.E. announces Dr Akiko Iwasaki as first recipient of inaugural ME/CFS Catalyst Award
DELFI Diagnostics CTO receives 2025 Most Influential Women in Bay Area Business recognition
RemeGen reports positive phase 3 results for disitamab vedotin in advanced urothelial carcinoma
Lilly and Purdue University expand collaboration, announce investment
AstraZeneca's Imfinzi improves disease-free survival in early bladder cancer trial